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1. Introduction 
Multiple myeloma (MM) is a clonal B cell malignant disease that is characterized by the 
proliferation of plasma cells in the bone marrow (BM) in association with monoclonal 
protein in the serum and/or urine, immune paresis, skeletal destruction, renal dysfunction, 
anemia, hypercalcemia and lytic bone diseases (Kyle & Rajkumar, 2004; Sirohi & Powles, 
2004). Although the introduction of conventional chemotherapy, high-dose therapy with 
hematopoietic stem cell transplantation (HSCT), and the development of novel molecular 
target agents has resulted in a marked improvement in overall survival, the disease still 
remains incurable (Attal & Harousseau, 2009; Lonial & Cavenagh, 2009). Alternative 
approaches are clearly needed to prolong the disease-free survival as well as the overall 
survival of patients with MM. To prolong the survival of patients with MM who are 
undergoing allogeneic HSCT, donor lymphocyte infusion can be used successfully as a 
salvage therapy, which is based on the graft-versus myeloma effect in some cases of MM 
that relapse after allogeneic HSCT (Harrison & Cook, 2005; Perez-Simon et al., 2003). This 
role of immune effector cells provides the framework for the development of immune-based 
therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as 
dendritic cells (DCs), in MM (Harrison & Cook, 2005). 
DCs are the most potent APCs for initiating cellular immune responses through the 
stimulation of naive T cells. Immature DCs are good at antigen uptake and processing, but 
for a stimulatory T cell response they must mature to become fully activated DCs, which 
express high levels of cell surface-related major histocompatibility complex (MHC)-antigen 
and costimulatory molecules. Because of their ability to stimulate T cells, DCs act as a link in 
antitumor immune responses between innate immunity and adaptive immunity 
(Banchereau & Steinman, 1998). These DCs play a central role in various immunotherapy 
protocols by generation of cytotoxic T lymphocytes (CTLs) (Reid, 2001). DC-based vaccines 
have become the most attractive tool for cancer immunotherapy and have been used in the 
treatment of more than 20 malignancies, most commonly melanoma, renal cell carcinoma, 
prostate cancer and colorectal carcinoma (Palucka et al., 2011; Ridgway, 2003). In MM, 
cellular immunotherapy using DCs is emerging as a useful immunotherapeutic modality to 
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treat MM (Ridgway, 2003). Since tumor antigen-loaded DCs are expected to be able to 
stimulate tumor-specific CTLs and to overcome T cell tolerance in tumor patients, the 
development of DC vaccines that can consistently eliminate minimal residual neoplastic 
disease remains an important goal in the field of tumor immunology (Banchereau & 
Palucka, 2005). 
2. Stream of DC research in MM 
MM is believed to induce immunoparesis that interferes with DC function, which 
diminishes the effective antitumor immune responses in these patients. Usually, ex vivo DCs 
are generated from circulating blood precursors (i.e. monocytes) or bone marrow progenitor 
cells and are educated with tumor antigens prior to vaccination to patients. Ex vivo 
generated DCs can be loaded with myeloma-associated antigens as vaccines for patients 
with MM. The use of immature DCs or mature DCs, the way to induce DC maturation, 
types of tumor antigens, the techniques to load tumor antigens to DCs, routes of 
administration, dosing schedules are being investigated (Figdor et al., 2004; Nestle et al., 
2001). 
2.1 Idiotype and idiotype-pulsed DCs in MM 
B cell malignancies are distinct from other types of cancer in that a tumor-specific antigen 
can be defined, namely the variable (V)-regions of the monoclonal immunoglobulin (Ig) that 
each B cell tumor clone produces. These V-region antigenic determinants are called 
idiotopes, and the sums of the idiotopes represent the idiotype (Id) of the monoclonal Ig. Id 
has distinct advantages as a tumor-specific antigen, which can be readily isolated from the 
plasma of MM patients (Hart & Hill, 1999). The Id protein has been used for 
immunotherapy both in vitro and in vivo in MM, and has demonstrated a successful 
response in follicular lymphoma and a unique expression of Id on the malignant B cell clone 
(Bergenbrant et al., 1996; Kwak et al., 1995). The first reported in 1971 demonstrated that Id 
is immunogenic in mice of the same inbred strain in which the myeloma cell originally 
developed (Sirisinha & Eisen, 1971). In addition, Id vaccination could induce both antibody 
and Id-specific T cells including CD4+ T cell and CD8+ T cell response by the presentation of 
Id protein on MHC class I and II of professional APCs. Id-specific CD4+ T cells appeared to 
be more frequent than CD8+ cells to response against Id protein. Id-specific CTL lines could 
be generated that killed autologous primary myeloma cells in vitro, and killing activity was 
induced by only MHC class I–restricted (Li et al., 2000), while in the other report both class 
I– and class II–restriction was observed (Wen et al., 2001). In MM, a number of studies 
using id vaccination in alone or in combination with cytokines and/or conjugate has been 
investigated. The Id protein was used as an autologous myeloma protein either alone 
(Bergenbrant et al., 1996) or combination with cytokine IL-2 with or without granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Hansson et al., 2007; Osterborg et al., 
1998; Rasmussen et al., 2003) or conjugation with keyhole limpet hemocyanin (KLH) to 
vaccinate myeloma patients (Coscia et al., 2004; Massaia et al., 1999). In general, Id-specific 
responses were observed with variable frequency, in which T cell and B cell responses were 
detected in vitro following Id vaccination, but clinical responses were unsatisfactory and the 
long time response was not observed. 
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Autologous DCs that were generated from MM patients have been shown to efficiently 
endocytose different classes of Id protein, and autologous Id-specific CTLs lines containing 
both CD4+ and CD8+ T cells that were generated by Id-pulsed DCs significantly recognized 
and killed the autologous primary myeloma cells in vitro (Butch et al., 2001; Wen et al., 
2001). Until now, the various studies of DC-based Id vaccination in MM have been reported 
(Bendandi et al., 2006; Lim & Bailey-Wood, 1999; Liso et al., 2000; Reichardt et al., 2003; 
Rollig et al., 2011; Titzer et al., 2000; Yi et al., 2002, 2010). Although Id-specific CTLs and 
immune response could be induced in some patients, clinical responses have been observed 
rarely in few patients after vaccination (Titzer et al., 2000). The Id-pulsed DC in combination 
with KLH (Liso et al., 2000; Yi et al., 2010), cytokine IL-2 (Yi et al., 2002) were used for 
vaccination in MM patients to improve the effectiveness of Id-pulsed DC vaccine. However, 
even both cellular and antibody responses have been observed, the clinical response also 
was not improvement following vaccinations. The reasons for these results may be 
attributed mainly to the Id protein as a weak antigen, and the use of immature DCs in some 
studies (Lim & Bailey-Wood, 1999; Osterborg et al., 1998; Wen et al., 1998). 
2.2 Myeloma-associated antigens-based DC immunotherapy 
Tumor-associated antigens (TAAs) have been identified in many tumor types including 
solid tumors and hematological malignancies. The highly specific TAAs such as the antigen 
that are present in one or only a few individuals and not found in normal cells for a 
particular tumor, or are only present in a number of related tumors from different patients 
or overexpress in increasing amounts in malignant cells were the greatest potential for 
clinically useful assays. Successful immunotherapy requires these sources of TAAs, which 
provide immune responses against the tumor cells or the cancer tissues that express the 
TAA on the tumors. A variety of myeloma-associated antigens have been identified in MM 
patients, which possibility provides an immune response by DC-based vaccine. Many 
potential TAAs in MM have been investigated including polymorphic epithelial mucin 
(MUC1), human telomerase reverse transcriptase (hTERT), PRAME, HM1.24, SP17, Wilms’ 
tumor I (WTI), Dickkopf-1 (DKK1), heat shock protein (HSP) gp96 or member of cancer 
germ-like family (MAGE, GAGE, BAGE, LAGE, NY-ESO-1) (Batchu et al., 2005; Brossart et 
al., 2001; Hundemer et al., 2006; Lim et al., 2001; Qian et al., 2007; Szmania et al., 2006). T 
cells from myeloma patients can recognize a variety of TAAs, which suggesting that the T-
cell has the capacity to kill myeloma cells selectively if these clonal populations can be 
activated and expanded effectively by a potent TAA. Among the various TAAs, some have 
been tested as peptide vaccines and only a few of them has been tested in vitro to induce 
TAA-specific CTLs response via loading the potent TAA to DCs in MM. The first TAAs 
pulsed with DCs in MM was MUC1, which was expressed on all of MM cell lines and 
primary myeloma cells and in sera of MM patients. Vaccination with MUC1 antigen has not 
been studied in MM patients, but MUC1-specific CTLs that were induced in vitro using 
peptide-pulsed DCs or plasma cell RNA-loaded DCs efficiently killed not only target cells 
pulsed with the antigenic peptide but also MM cells (Brossart et al., 2001; Milazzo et al., 
2003). NY-ESO-1 is the most immunogenic of the cancer testis antigens, which are expressed 
in a variety of tumors, while their presence in normal tissue is limited to the testis and 
placenta (Szmania et al., 2006). In MM, expression of NY-ESO-1 has been correlated with 
more advanced disease (van Rhee et al., 2005). Spontaneous humoral and CD8+ T cell-
mediated responses to NY-ESO-1 have been identified in patients with advanced disease 
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(Szmania et al., 2006; van Rhee et al., 2005). Although the clinical trial using NY-ESO-1 with 
DCs has not been tested, the in vitro monocyte-derived DCs transduced with the PTD-NY-
ESO-1 protein can induce CD8+ cellular antitumor immunity superior to that achieved with 
NY-ESO-1 protein alone (Batchu et al., 2005). Sperm protein 17 (Sp17), the other 
immunogenic TAA, has been used as a tumor antigen to load into DCs. Sp17-specific HLA 
class I-restricted CTLs were successfully generated by DCs that have been loaded with a 
recombinant Sp17 protein and the CTLs were able to kill autologous tumor cells that 
expressed Sp17 (Chiriva-Internati et al., 2002). The over-expression of hTERT on MM 
compared to normal cells indicated that this telomerase could be used as tumor antigen to 
induce antitumor immune responses (Vonderheide et al., 1999). hTERT was capable of 
triggering antitumor CTL responses and kill hTERT+ tumor cells (Vonderheide et al., 1999). 
Recently, the activated T lymphocytes that were stimulated by DCs loaded with hTERT- and 
MUC1-derived nonapeptides were successfully able to kill myeloma cell line (Ocadlikova et 
al., 2010). DKK1, a novel protein that is not expressed in most normal tissues but is 
expressed in almost myeloma cells, could be a potentially important antigenic target for 
antimyeloma immunotherapy (Qian et al., 2007). DKK1-specific CTLs that were generated 
by DCs pulsed with DKK1 peptides were specifically lysed autologous primary myeloma 
cells and DKK1-positive cell line (Qian et al., 2007). In general, TAAs could be a major 
interest in immunotherapy in MM. However, problems that should be solved before starting 
the clinical trials include defining whether a specific TAA is a suitable and safe for 
immunotherapy of patients with MM. One problem was that TAA susceptible of inducing 
autoimmunity provided that autoimmunity remains limited to some tissues or is 
controllable. The other problem was that some members such as Sp17 and MUC1 have been 
detected in normal tissues; therefore, it remains to be elucidated whether specific CTLs are 
able to recognize only myeloma cells. Furthermore, although the other TAA such as PRAME 
and Sp17 could be over-expressed on almost MM cell lines, only a small number of tumor 
samples from MM patients showed a similar level, limiting its usefulness as an isolated TAA 
in MM. To overcome the effect of TAAs-based immunotherapy, trials involving more than 
one TAA need to be designed. Taken together, the data support DC immunotherapy with 
TAAs as being a promising immunotherapy to support to clinical trials in MM. 
2.3 Whole tumor antigen-based DC immunotherapy 
An alternative to Id protein- or TAA-based immunotherapy in MM is to use other tumor 
antigens that derived from whole tumor preparation to improve the efficacy of the DC 
vaccination in patients with MM. Although a single TAA has the possibility to induce the 
antitumor immune responses against MM, tumors may escape immune recognition by 
down-regulating expression of a particular antigen. In contrast, DCs loaded with antigens 
derived from whole tumor cells can improve the antitumor response and that limits the risk 
for immunological escape. There have been increasing reports of these alternative 
approaches, such as DCs pulsed with myeloma lysates (Hayashi et al., 2003; Lee et al., 2007; 
Wen et al., 2002), DCs pulsed with myeloma apoptotic bodies (Nguyen-Pham et al., 2011; 
Yang et al., 2010; Yang et al., 2011), DCs transfected with myeloma-derived RNA (Milazzo et 
al., 2003), DCs pulsed with myeloma-derived HSP gp96 (Qian et al., 2005; Qian et al., 2009), 
or DC-myeloma cell hybrids (Gong et al., 2002; Hao et al., 2004; Vasir et al., 2005). These 
techniques have the advantage of allowing the presentation of multiple epitopes to MHC on 
DCs, therefore can induce polyclonal T cell response from many potentially unknown TAAs 
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and reduce the probability of immune escape by single TAA. The first study reported that 
bone marrow mononuclear cells from the patients with MM contained more than 90% 
CD138+CD38+ myeloma plasma cells and CTLs that were generated by DCs loaded with 
myeloma cell lysates demonstrated much stronger cytotoxicity against autologous plasma 
cells than did those by Id protein-pulsed DCs, which suggested the superiority of the 
myeloma cell itself as a source of a tumor antigen compared with the Id protein (Wen et al., 
2002). In other myeloma model, DCs pulsed with purified and optimized myeloma cell 
lysate were shown to generate CTLs that killed autologous tumor cells but not against 
mismatch HLA cell lines or K562 cell lines in vitro (Lee et al., 2007). The apoptotic bodies 
derived from either myeloma cell lines or patient’s myeloma cells also have been used as 
tumor antigen to loading with DCs. Interestingly, apoptotic bodies were shown to be more 
effective than cell lysate at inducing CTLs against autologous myeloma cells (Hayashi et al., 
2003). Heat shock proteins (HSPs) are a class of functionally related proteins whose 
expression is increased when cells are exposed to elevated temperatures or other stress. 
Tumor-derived HSPs, such as HSP70 and gp96, are immunogenic and potent in stimulating 
the generation of tumor-specific CTLs. Myeloma-derived gp96 has been obtained and used 
to pulse DCs to generate the specific CTLs in MM. The specific CTLs was able to lyse 
myeloma tumor cells but not normal blood cells in a MHC class I–restricted manner and 
provide a rationale for gp96-based immunotherapy in MM (Qian et al., 2005; Qian et al., 
2009). In other way, a promising vaccine strategy in which the autologous DCs were fused 
with patient-derived tumor cells has been developed. DC fused with tumor can stimulate 
both helper and cytotoxic T cell responses through the presentation of internalized and 
newly synthesized antigens (Vasir et al., 2005). In mouse MM models, vaccination with DCs 
fused with either myeloma cells or tumor cells that were genetically modified to express 
CD40L resulted in eradication of disease in tumor-bearing animal and protective against 
subsequent tumor challenge in animals (Gong et al., 2002; Hao et al., 2004). Recently, a phase 
1 study in which patients with MM underwent serial vaccination with the DC fused with 
MM cell fusions in conjunction with GM-CSF (Rosenblatt et al., 2011) resulted in the 
expansion of circulating CD4+ and CD8+ lymphocytes reactive with autologous myeloma 
cells in 11 of 15 MM patients and a majority of patients with advanced disease demonstrated 
disease stabilization. In general, the production of DC vaccine by using whole tumor 
antigens has become promising in order to induce immunotherapy against MM. 
3. Innovative researches in the field of DC vaccination 
3.1 Immune disorder in MM 
Usually, hematologic malignancies elicit measurable, albeit weak, immunogenic responses 
that are generally unable to mediate tumor destruction. They are able to escape immune 
surveillance by down-regulation of immune markers such as costimulatory molecules and 
MHC class I and II molecules as well as through the production of immunosuppressive 
cytokines by the tumor cells or by activation of suppressor cells such as regulatory T cells 
(Treg) and myeloid-derived suppressor cells (MDSCs) (Kim et al., 2007). In particularly, MM 
induces immune paresis (Quach et al., 2010). Patients with MM have basically dysfunctional 
DCs that are functionally defective, evidenced by the decreased number of circulating 
precursors of DCs as well as impaired T cell stimulatory capacity (Brown et al., 2001; Ratta 
et al., 2002; Tucci et al., 2011). DCs in MM patients are a target of tumor-associated 
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suppressive factors, such as interleukin (IL)-10, transforming growth factor beta (TGF-), 
vascular endothelial growth factor (VEGF), and IL-6, resulting in their aberrant functions 
and impaired development of effector functions in tumor-specific lymphocytes (Brown et 
al., 2001; Ratta et al., 2002). In addition, the survival and proliferation of tumor cells is 
partially facilitated by the impaired endogenous immune surveillance against tumor 
antigens (Zou, 2005). Myeloma cells can produce immunoinhibitory cytokines, such as TGF-
, IL-10, IL-6 and VEGF, which play major roles in the pathogenesis of MM (Brown et al., 
2001; Ratta et al., 2002). These tumor-derived factors can also modulate anti-tumor host 
immune responses, including the abrogation of DC function, by constitutive activation of 
the signal transducer and activator of transcription 3 (STAT3) (Yu et al., 2007). Impairment 
in both humoral and cellular immunity in MM is associated with impaired B cell 
differentiation and antibody responses (Brown et al., 2001), reduced T cell numbers 
specifically CD4+ T cells and abnormal Th1/Th2 CD4+ T cell ratio (Ogawara et al., 2005), 
impaired CTL responses (Maecker et al., 2003), and dysfunction of NK cells (Jarahian et al., 
2007) and NKT cells (Dhodapkar et al., 2003). In addition, dysregulation of natural 
CD4+CD25+T regulatory (Treg) has been reported (Prabhala et al., 2006). Tregs are a group 
of immuno-suppressive T cells that have been implicated in the suppression of tumor 
immunity (Curiel, 2007). A higher number of Tregs were reported in myeloma capable of 
suppressive activity at T cell stimulation (Beyer et al., 2006). Recently, a human study 
reported that the proportion of CD4+FOXP3+ Treg cells was increased in MM patients at 
diagnosis and Treg cells from patients with MM were functionally intact as they were able 
to inhibit proliferation of both CD4 and CD8 T cells (Brimnes et al., 2010). More recently, the 
discovery of myeloid-derived suppressor cells (MDSCs) revealed these cells as potent 
suppressors of tumor immunity and, therefore, a significant impediment to cancer 
immunotherapy (Ostrand-Rosenberg & Sinha, 2009). MDSCs are a heterogeneous 
population of cells of myeloid origin, which are present and accumulate in most cancer 
patients and experimental animals with cancer, and which are considered as a major 
contributor to the profound immune dysfunction of most patients with sizable tumor 
burdens (Ostrand-Rosenberg & Sinha, 2009). MDSC levels in cancer patients are driven by 
tumor burden and by the diversity of factors produced by the tumor and by host cells in the 
tumor microenvironment (Gabrilovich & Nagaraj, 2009). MDSCs suppress antitumor 
immunity through a variety of diverse mechanisms (Gabrilovich & Nagaraj, 2009). MDSCs 
can suppress the activation of T cells, B cells, natural killer (NK) cells and NKT cells. In 
contrast, MDSCs can enhance the induction of Tregs. Antigen presentation is also limited by 
the expansion of MDSC at the expense of DCs. Recently, an increase in the proportion of 
CD14+HLA-DR-/low MDSC in patients with MM at diagnosis was described, illustrating that 
this cell fraction is also distorted in patients with MM (Brimnes et al., 2010). Taken together, 
the immune paresis in patients with MM suggested that DC-based vaccine therapies in MM 
need to be boosted with other alternative approaches or potent DCs may be needed to 
increase the effectiveness of vaccination. 
3.2 Key points to improve DC vaccination in MM 
For improving clinical outcomes using DC-based immunotherapy, there have been 
increasing reports of alternative approaches, such as better cytokine combinations to 
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enhance DC function, effective tumor antigens to induce specific CTLs, or modifying signal 
transcriptions to overcome defective DC function. Our experience in the DC research field 
has revealed several key points to improve DC vaccination in cancer patients (Fig. 1). 
 
Fig. 1. Key points to improve DC vaccination in cancer patients. Abbreviations: CTL, 
cytotoxic T lymphocyte; DCs, dendritic cells; TA, tumor antigen; LNs, lymph nodes; Treg, 
regulatory T cell; MDSC, myeloid-derived suppressor cell. 
As described above, the results of immunotherapy with Id-pulsed DCs have been 
unsatisfying. An alternative to Id protein is to use other tumor antigens that improve the 
efficacy of the DC vaccination in patients with MM. The selected antigen should possess the 
best characteristics to induce high cross presentation, be tumor specific, be easily available, 
but be unable to induce immune suppression. Whole tumor antigens is the best tumor 
antigen, which has been selected by many investigators including myeloma cell lysates 
(Kortylewski et al., 2005; Lee et al., 2007; Nefedova et al., 2005; Nefedova & Gabrilovich, 
2007; Wang et al., 2006; Wang et al., 2006), apoptotic bodies from myeloma cell line (Lee et 
al., 2007; Nguyen-Pham et al., 2011; Yang et al., 2010), and apoptotic allogeneic myeloma 
cells from other patients with matched subtype (Yang et al., 2011). In practical terms, there 
are a number of patients with MM, who have less than 50% of myeloma cells in the bone 
marrow at the time of diagnosis or during progression of the disease. When mononuclear 
cells from the bone marrow are used as a source of tumor antigens, there is the potential of 
contamination with normal cells, especially lymphocytes. Thus, it is necessary to use 
purified and optimized myeloma cells, if possible, as a source of tumor antigen for the 
generation of myeloma-specific CTLs stimulated by DCs (Lee et al., 2007). We have shown 
that the function of the DCs was affected by the concentration of myeloma cell lysates (i.e., 
higher concentrations of lysates suppress T cell stimulatory capacities more than lower 
concentration of lysates). Also, the optimization of the lysate concentration did not 
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demonstrate any inferiority in functions, such as T cell stimulatory capacities and 
cytotoxicities, of the DCs compared with other antigens, such as apoptotic bodies of 
myeloma cells or formalin-fixed myeloma cells. CTLs that were generated by purified and 
optimized myeloma cell lysates pulsed with DCs demonstrated much stronger cytotoxicity 
against autologous plasma cells. These findings indicate that it is important to optimize the 
concentration of myeloma cell lysates that were loaded onto DCs to potentiate their 
function.  
The use of whole tumor cells, instead of single antigens, may help to enhance antitumor 
effects but target multiple tumor variants and counteract tumor immune evasion. However, 
it is impractical to obtain sufficient amounts of purified autologous myeloma cells for tumor 
antigens in the clinical setting of patients with MM. As an alternative source of tumor-
relevant antigens, allogeneic tumor cells or established cancer cell lines have been used to 
overcome this limitation in various tumors (Koido et al., 2005; Lee et al., 2007; Palucka et al., 
2006; Yang et al., 2010). Allogeneic myeloma cell lines used as universal tumor antigens 
could substitute for an original tumor cell collection and make the culture of tumor cells 
easier. In clinical practice, allogeneic myeloma cell lines might be an effective source of 
universal tumor antigen that could be used to load DCs for the generation of myeloma-
specific CTLs in MM patients. Tumor antigens that derived from irradiated allogeneic 
myeloma cell line when loaded with DCs could generate myeloma-specific CTLs against 
autologous myeloma cells in patients with MM (Nguyen-Pham et al., 2011; Yang et al., 
2010). These findings suggest that allogeneic myeloma cell lines are potent immunogens 
capable of inducing functional CTLs against patients' own tumor cells. The success of using 
an allogeneic myeloma cell line as tumor antigen led to the possibility that allogeneic 
myeloma cells could be also used as a viable source of tumor antigen in the context of 
appropriate major MHC alleles to autologous CTLs. We investigated the possibility of DC 
therapy using autologous DC loaded with apoptotic allogeneic myeloma cells from the 
matched monoclonal subtype of myeloma patients and showed that the CTL generated by 
these tumor antigens loaded-DCs could generate myeloma-specific CTLs against autologous 
myeloma cells in patients with MM (Yang et al., 2011). These findings suggested that the 
allogeneic matching monoclonal immunoglobulin subtype of myeloma is an effective tumor 
antigen capable of inducing functional CTLs against patients' own tumor cells. 
The suppressive effects of tumor cells during DC generation have been explained previously 
by the ability of the tumor microenvironment to suppress DC differentiation (Savill et al., 
2002; Yu et al., 2007). The suppression is due to the activation of STAT3 and the production 
of immunosuppressive factors, such as VEGF, IL-10, and IL-6. These factors can influence 
STAT3 and extracellular signal-regulated kinase (ERK) phosphorylation, resulting in 
hyperactivation of STAT3 and ERK, which may be responsible for defective DC 
differentiation (Kitamura et al., 2005; Yu et al., 2007). In addition to generation of potent and 
specific tumor antigen-loaded DCs for vaccination, alternative methods have attempted to 
restore defective DC function and to enhance DC function in MM. Enhanced immune-
mediated antitumor effects of DCs have been reported following the inhibition of the janus-
activated kinase 2 (JAK2)/STAT3 pathway (Nefedova et al., 2005), inhibition of p38 or 
activation of the MEK/ERK or mitogen-activated protein kinase (MAPK) pathways, and 
neutralizion of IL-6 (Wang et al., 2006). Recently, we reported that the inhibitory factors and 
abnormal signaling pathways of DCs during maturation with tumor antigen might be 
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responsible for the defective activity of DCs in MM, and suggested that the way to 
overcome these abnormalities is by neutralizing the signaling that would lead to a 
suppressed immune response (Yang et al., 2009). More recently, we are developing of the 
strategies that recovering dysfunction of DCs caused from loading tumor antigen through 
the treatment of a combination of the selective JAK/STAT3 signaling pathway inhibitor (JSI-
124) and the proteasome inhibitor (Bortezomib) onto myeloma cells (Lee et al., 2011). We 
reported that pretreatment of myeloma cells with combination of JSI-124 and bortezomib 
can recover DC dysfunction from loading the dying myeloma cells through the up-
regulation of Hsp90 and the down-regulation of STAT3 phosphorylation and inhibitory 
cytokines production, and these DCs can generate to potent myeloma-specific CTLs. 
For effective induction of tumor-specific immune responses in the field of DC vaccination, 
the DCs should have potency to stimulate T cells, to produce high levels of Th1 polarized 
cytokines (IL-12p70), to trigger Th1 polarizing capacity, and to migrate through lymphatic 
vessels to interact with T cells. Therefore, the strategy to generate the fully functional and 
potential DCs has been developed. The initial success of the therapeutic vaccines involving 
immature or partially-mature ”first-generation” DCs has been reported (Hsu et al., 1996). 
However, such DCs express suboptimal levels of co-stimulatory molecules, and constitute a 
weaker immunogen than the subsequently-implemented mature DCs, constituting the 
"second generation" of clinically-applied DCs (sDCs). sDC vaccines induced by the IL-
1/TNF-/IL-6/prostaglandin E2 (PGE2) cytokine cocktail have been developed (Jonuleit et 
al., 1997). Such DCs are fully-mature DCs with high expression of co-stimulatory molecules, 
high expression of CCR7, and high migratory responsiveness to LN-associated chemokines; 
they have been widely tested in clinical trials. However, to date, the sDC vaccines have 
limitations that include the mediation of Th2 polarization, promotion of DC secretion of the 
immunosuppressive cytokine IL-10, inability to induce effectively the Th1-type response 
(because PGE2 abolishes the secretion of IL-12p70), and high activity of such DCs in 
activating Treg cells (Banerjee et al., 2006; Kalinski et al., 1997, 2001; Yamazaki et al., 2006). 
Several investigators, including our group, have tried to develop the potent DCs for 
inducing effective tumor-specific immune responses. In an attempt to increase DC potency 
using cytokine combinations, -type-1-polarized DCs (DC1s) that are induced to mature 
using the DC1-inducing cytokine cocktail IL-1, TNF-, IFN-, IFN-, and 
polyinosinic:polycytidylic acid [poly(I:C)]) has been developed to generate strong functional 
CTLs in several diseases, on average 20-fold higher compared to sDCs (Lee et al., 2008; 
Mailliard et al., 2004). Recently, we successfully generated DC1s from a patient with MM 
with high expression of costimulatory molecules, significant production of IL-12p70, and 
potent generation of myeloma specific CTLs (Yang et al., 2010, 2011). The potential of 
polarized DC1s to produce IL-12 has important implications for the use of DCs as cancer 
vaccines. 
The other strategy to induce potent DCs from patients with MM was the use of a ”helper” 
cell to promote type 1 polarization of DCs. DCs and NK cells reciprocally activate each other 
during the immune response. Recent data from our and other groups demonstrate that such 
NK–DC interaction promotes the subsequent induction of tumor-specific responses of CD4+ 
and CD8+ T cells, allowing NK cells to act as ”helper” cells in the development of the type 1 
DCs in responses against cancer (Mailliard et al., 2003; Nguyen-Pham et al., 2010, 2011). 
Resting NK cells that are activated in the presence of TLR agonist, IL-2, and IFN- can 
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induce DCs from patients with MM maturation and enhance IL-12p70 production in vitro. 
These potent DCs can be developed to generate strong functional CTLs against myeloma 
cells compared to sDCs (Nguyen-Pham et al., 2011). 
Therapeutic DC vaccines against cancer not only need to be highly effective in inducing the 
expansion of tumor-specific T cells, but they also need to avoid interaction and induction of 
Tregs. Recently, the type 1-polarized DCs were demonstrated to suppress the secretion of 
CCL22 (Treg and Th2 type attracting chemokines), enhance the secretion of CCL5 and 
CXCL10 (Th1 and effector T cell-attracting chemokines), and suppress the induction of Tregs 
compared to sDCs or PGE2-matured DCs (Muthuswamy et al., 2008). DCs generated in vitro 
for vaccination protocols that can target a local lymph node are highly sought, but difficult 
to achieve in practice. Type 1-polarized DCs, with higher levels of IL-12p70 and potent CTL 
generation targeting, are, however, limited by their migratory capacity to primary lymph 
organs due to the relatively lower expression of CCR7 compared to sDCs. We recently 
reported on the nature of the enhancement of the migratory phenotype of DCs. The first 
important mediator in the mobilization of DCs to lymph nodes is CCR7. However, 
upregulation of CCR7 alone by DCs is insufficient to drive DC migration toward CCL19 and 
CCL21. Up-regulation of CD38 and down-regulation of CD74 regulate DC migration in vitro 
and in vivo (Faure-Andre et al., 2008; Frasca et al., 2006). By regulating CD38, CD74, and 
CCR7 expression on DCs, type I and II IFNs have synergistic effects in the presence of TLR 
agonists on the regulation of DC migration and may provide a novel approach to improving 
vaccination efficacy (Nguyen-Pham et al., 2011). 
Finally, to enhance the antitumor effectiveness of DC-based vaccines in preclinical in vivo 
mouse models, we have developed several models of combination therapy of DCs with an 
immunomodulatory drugs, such as cyclophosphamide or lenalidomide. Cyclophosphamide 
is frequently used to enhance or augment the antitumor effects in cancer immunotherapy 
(Ghiringhelli et al., 2004; Mihalyo et al., 2004). The possible effect of cyclophosphamide to 
enhance the antitumor efficacy of DC vaccine may be due to the increasing proportion of 
IFN- secreting lymphocytes in combination with the suppressing proportion of 
CD4+CD25+FoxP3+ Treg cells in tumor-bearing mice (Liu et al., 2007). The result of a clinical 
trial using allogeneic DC vaccine combined with low-dose cyclophosphamide has revealed 
that the combination therapy could induce stronger antitumor response compared with DC 
vaccine alone (Holtl et al., 2005). Recently, we developed a combination therapy in mouse 
cancer model which showed that a single administration of low-dose cyclophosphamide 
before the first DC vaccination augmented the antitumor effects of DC vaccine to eradicate 
tumor completely and consequently prolonged the survival of vaccinated mice (Pham et al., 
2010). We are now developing a clinical trial in MM patients using this combination therapy. 
4. DC-based vaccine in published clinical trials 
Clinical trials of DC-based vaccine for MM have been restricted until now. The trial protocol 
and responses are summarized in Table 1. Almost of the clinical trials were related with 
using Id-pulsed DC alone or in combination with adjuvant such as cytokines or KLH. In the 
decade after the first DC-based Id vaccination was started at Stanford University, the results 
of clinical trials were limited. In general, the majority of clinical trials conducted using  
Id-pulsed DCs showed immune responses. However, the clinical responses were 
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unsatisfactory, mainly due to the poor immunogenicity of the Id protein. More recent results 
demonstrated improved clinical response by DC-based Id vaccination (Rollig et al., 2010; Yi 
et al., 2010). Therefore, DC-based Id vaccination is a possible way to induce the specific T 
cell responses in myeloma patients. Further trials with increasing numbers of patients are 
needed to increase the rate of responses. 
Most recently, a phase I study was undertaken, in which patients with MM were vaccinated 
with an autologous DC/tumor cell fusion in combination with GM-CSF administration on 
the day of DC vaccination (Rosenblatt et al., 2011). Vaccine generation was successful in  
17 of the 18 patients. The expansion of circulating CD4+ and CD8+ T cells reactive with 
autologous myeloma cells in 11 of 15 evaluable patients were detected. A majority of 
patients (11 of 16) with advanced disease demonstrated disease stabilization, with three 
patients showing ongoing stable disease at 12, 25, and 41 months. Interestingly, antibody 
response against some TAAs, such as regulators of G-protein signaling 19 (RGS19), HSP90, 
BRCA1-associated protein (BRAP) was also detected. So, vaccination with DC/MM fusions 
was feasible and may provide a new source of DC-based vaccines for the development of 
immunotherapy against MM. 
A commercial product is currently being tested in a phase III trial (MylovengeTM, Dendreon 
Corp, Seattle, WA, USA). Mylovenge (APC8020) is conducted by pulsing autologous DCs 
with the patient's Id. A recent report of this commercial product showed that the long-term 
survival of those receiving the vaccine compared to all other patients with MM who 
underwent autologous HSCT (Lacy et al., 2009). This approach needs further testing in a 
phase III trial to confirm the clinical response and define the role of this DC vaccine in MM. 
We are also conducting a phase I/II clinical trial using type 1-polarized DCs loading with 
tumor antigens derived either from allogeneic myeloma cell line or patient’s autologous-
/allogeneic- myeloma cells in combination with chemotherapy in patients with MM after 
autologous HSCT. 
5. Future perspectives 
Despite their relative limitations, the data from recent clinical studies have suggested that 
DC-based vaccine may be a potential therapy in inducing the rate of tumor responses and 
prolonging the survival of patients with MM. In an attempt to increase DC-based potency 
and improve immune responses following vaccination, further investigations of additional 
tools to identify the alternative tumor antigens uniquely or specifically expressed on 
myeloma cells are needed, to recover or restore the dysfunction of DCs in MM patients, to 
induce T cells with the desirable effector functions rather than regulatory functions, to 
migrate into lymph nodes to stimulate T cells, and to clarify the ability of tumor specific 
CTLs to recognize and kill tumor cells. In our expectation, type 1-polarized DCs can be 
developed to generate strong functional CTLs. The allogeneic myeloma cell lines or 
allogeneic myeloma cells might be an effective source of universal tumor antigen that could 
be used to load to the DC1s for the successful generation of myeloma-specific CTLs. 
Eventually, the combination therapy, in which a DC vaccine is combined with either 
alternative therapy including chemotherapy, radiation therapy, molecular target therapy or 
other immunotherapy (adoptive therapy, NK cells therapy) or with adjuvant, will provide 
vigorous and maintained immune responses with the benefit clinical efficacy. 
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Author DC type TA Adjuvant Immune responses Clinical responses 
Liso et al. imDC Id  KLH 4/24 Id-specific  17/26 SD 
Lim et al. imMo-DC Id KLH 5/6 Id-specific; 2/6 Id-
specific IFN-; 3/6  
increase in Id-specific  
CTL frequency 
6/6 PD 
Reichardt 
et al. 
imDC Id none 2/12 Id-specific 
proliferation; 1/3 Id-
specific CTL 
2 relapse; 8/10 PD; 
2/10 SD 
Titzer  
et al. 
CD34-DC Id none 4/10 Id-specific T cell 
proliferation; 1/10 
decreased BM 
plasmacytosis 
1/10 SD; 9/10 PD 
Cull et al. imMo-DC Id none 2/2 Id-specific T cell 
proliferation; no Id-
specific CTL response 
2/2 PD 
Yi et al. mMo-DC Id Il-2 2/5 Id-specific T cell 
proliferation; 5/5 Id-
specific B cell  
proliferation;  
4/5 Id-specific IFN- 
1/3 PR; 3/5 SD; 1/5 
PD 
Bendandi 
et al. 
mMo-DC Id none 4/4 anti-KLH response; 
2/4 Th1 cytokines 
response 
1/4 SD; 3/4 PD 
Lacy  
et al. 
APC8020 
(Mylovenge)
Id none None reported 6/26 CR; 2/26 PR; 
19/27 SD 
Overall survival: 5.3 
years of follow-up for 
alive patients 
Lacy  
et al. 
CD40 L-DCs Id KLH 9/9 Id-specific IFN-; 5/9 
Id-specific CTL response; 
8/9 anti-KLH response 
6/9 SD; 3/9 slowly PD 
4/6 continue SD after 
5 years 
Rosenblatt 
et al. 
DC/tumor 
fusion 
 GM-CSF 11/15 CD4 and CD8 
response with autologous 
myeloma cells; 5/5 tested 
anti-MUC1 response 
11/16 SD (3/11 > 1 
years SD; 8/11 2.5-5 
months SD) 
Rollig  
et al. 
mMo-DC Id KLH 5/9 Id-specific T cell 
proliferation;  
8/9 Id-specific  
cytokines response;  
 
3/9 M protein 
decrease; 5/9 M 
protein stable 
Table 1. Summary of Clinical trials of DC-based vaccine for MM. Abbreviations: DC, 
dendritic cell; TA, tumor antigen; imDC, immature DC; Mo-DC, monocyte-derived DC; Id, 
idiotype; mMo-DC, mature Mo-DC; KLH, keyhole limpet hemocyanin; CTL, cytotoxic T 
lymphocyte; PD, progressive disease; PR, partial response; SD, stable disease; CR, complete 
response 
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